In recent years, the biotech financing landscape has been in a period of tumult, with ever-growing competition and shifts in the global policy landscape contributing to a challenging fundraising environment.
While various hurdles remain, biotechs must still find a way to attract investor attention to secure capital to fund their drug development efforts and build up their all-crucial data packages.
In this episode of the GlobalData Healthcare Podcast, recorded at the 2026 Outsourcing in Clinical Trials and Clinical Trial Supply Nordics conference, held in Copenhagen, Denmark, Clinical Trials Arena reporter, Annabel Kartal-Allen, chats with Stephan Christgau, founding partner at Eir Ventures.
He discusses what looks for in a biotech when making investment decisions, and what is catching his eye as an investor in a sea of innovation.
Christgau also elaborates on the importance of developing an effective clinical strategy to garner the trust of a prospective investor – diving into what separates a good data package from a great one, and what he looks for in this realm when allocating capital.
If you liked this episode of the GlobalData Healthcare podcast, you can find a range of episodes, which bring you key insights into the world of pharma, biotech, medical devices and clinical trials, at this link.
A detailed agenda for the 2nd Annual Outsourcing in Clinical Trials China 2026 conference and Clinical Trial Supply China 2026 conference can be accessed here. The conference is hosted by Arena International Events Group, a B2B events company owned by GlobalData, the parent company of Clinical Trials Arena and Pharmaceutical Technology.
Interested in attending or sponsoring OCT China and CTS China? Complete the form below, and the Arena team will be in touch.


